Hope for cystic fibrosis patients

May 2, 2016 News BioVox

Galapagos NV and AbbVie announced that the companies have expanded their collaboration focused on the discovery, development and commercialization of therapy options for cystic fibrosis (CF). In people with this life-threatening genetic disorder (80,000 worldwide) mutations in the CF gene cause the CFTR protein to malfunction, affecting chronically the lung and digestive systems and eventually leading to their destruction. Currently there is no cure for CF and the patients require lifelong supportive treatment and organ transplantation.

By developing a breakthrough triple CFTR combination therapy, Galapagos and AbbVie aim to offer new therapy options to 90% of the CF patients. “The compounds in our CF franchise show exciting results in vitro, and our strong partnership with AbbVie is focused on getting these combinations into patient trials as soon as possible”  says Onno van de Stolpe, CEO of Galapagos.

AbbVie increased the potential milestones to Galapagos for Phase 1 and 2 achievements, bringing the remaining total milestone payments in the CF alliance up to nearly $600million. AbbVie has made an upfront payment of $45 million to Galapagos, which is in charge of   the Phase 2 clinical development. Phase 3 will be executed by AbbVie and financially supported by Galapagos.


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts